enGene grants 231,000 stock options to interim CMO

enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards.

Rhea-AI Filing Summary

enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.

He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 231,000 shares

Grant/Award 2 txns

Insider Grossman William

Role Interim Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	200,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 231,000 contracts (Direct)

Footnotes (2)

1. F1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board.
2. F2. This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company.

Key Figures

Director option grant size: 200,000 shares Executive option grant size: 31,000 shares Exercise price: $1.75 per share +3 more

6 metrics

Director option grant size 200,000 shares Underlying common shares for non-executive director option grant

Executive option grant size 31,000 shares Underlying common shares for Interim Chief Medical Officer option grant

Exercise price $1.75 per share Exercise price for both option grants

Director options post-grant 200,000 options Total options following transaction for 200,000-share grant

Executive options post-grant 31,000 options Total options following transaction for 31,000-share grant

Option expiration June 16, 2036 Expiration date for both option awards

Key Terms

Stock Option (Right to Buy), vesting commencement date, exercise price, expiration date, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vesting commencement date financial

"the first anniversary of the vesting commencement date, which was June 9, 2026"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercise price financial

"conversion_or_exercise_price: 1.7500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Interim Chief Medical Officer financial

"subject to the reporting person's continued service as Interim Chief Medical Officer"

non-executive director financial

"for his service as a non-executive director, consistent with annual grants"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did enGene Therapeutics (ENGN) report for William Grossman?

William Grossman received two stock option grants. One covers 200,000 common shares and the other 31,000 shares, both at a $1.75 exercise price. These are compensation awards, not open-market purchases or sales, and relate to his director and Interim Chief Medical Officer roles.

How many enGene Therapeutics (ENGN) shares are covered by Grossman’s new options?

The reported grants cover options on 231,000 common shares in total. One award is for 200,000 underlying shares and the second for 31,000 underlying shares, each providing the right to buy common shares at a fixed exercise price if and when the options vest.

What is the exercise price and expiration date of Grossman’s ENGN stock options?

Both option grants have an exercise price of $1.75 per common share and an expiration date of June 16, 2036. This means Grossman may choose to exercise vested portions any time before expiration, subject to the specific vesting conditions described in the awards.

How do the 200,000-share ENGN options granted to Grossman vest?

The 200,000-share option vests fully on the earlier of two events: the first anniversary of the June 9, 2026 vesting commencement date, or enGene Therapeutics’ 2027 annual shareholder meeting. This award compensates Grossman for his service as a non-executive director on the company’s board.

What are the vesting terms for Grossman’s 31,000-share ENGN option grant?

The 31,000-share option vests in substantially equal monthly installments over 12 months, on the 12th day of each month. Vesting is conditioned on Grossman’s continued service as enGene Therapeutics’ Interim Chief Medical Officer at each vesting date, aligning the award with his ongoing executive role.

Are Grossman’s ENGN option grants part of a routine compensation program?

Yes. The 200,000-share option was granted consistent with annual grants to other non-executive directors. The 31,000-share option was granted in connection with Grossman’s appointment as Interim Chief Medical Officer, reflecting standard equity-based compensation tied to board and executive responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman William

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.75	06/16/2026		A		31,000		(1)	06/16/2036	Common Shares	31,000	$0	31,000	D
Stock Option (Right to Buy)	$1.75	06/16/2026		A		200,000		(2)	06/16/2036	Common Shares	200,000	$0	200,000	D

Explanation of Responses:

1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board.

2. This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company.

	/s/ Lee Giguere, as attorney-in-fact for the Reporting Person	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)